Coherus Q2 FY26 net loss narrows 25.67% to $33.3 million; revenue rises 39.51% to $14.3 million

Reuters2026/08/05 22:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Coherus Oncology posted Q2 2026 revenue of USD 14.3 million, up 39.53% from a year earlier.
Net loss from continuing operations narrowed to USD 33.3 million, or USD 0.22 per share, from USD 44.9 million, or USD 0.39 per share.
LOQTORZI net revenue rose 15% from Q1 2026 to USD 13.6 million, with strong demand and the most new patient starts since launch.
R&D expense fell to USD 21.4 million from USD 26.3 million, on reduced headcount and lower trial and manufacturing costs.
Cash, cash equivalents and marketable securities totaled USD 105.3 million at June 30, 2026, down from USD 172.1 million at Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

U.S. Treasury Secretary Janet Yellen stated on Tuesday that the Treasury's decision last month to expand the buyback program for older-dated U.S. Treasury bonds was mainly aimed at "cooling down" the bond market, which has been heating up recently, and helping the market return to a more balanced state.

智通财经•2026/09/08 22:41